48200 Results for: "3-(Methylsulphonyl)benzyl+bromide&pageNo=8"

A potent chloride channel blocker (IC50=0.1-100 µM depending on channel subtype and assay method). Inhibits cyclooxygenase (COX; IC50=8 µM). Evidence of mitochondrial uncoupling in mouse peritoneal macrophages, due to protonophore activity.

Expand 2 Items

Fipronil ≥98%

Supplier: ENZO LIFE SCIENCES

Cl⁻ channel blocker.

Expand 1 Items

Hydroxy-2-naphthalenylmethylphosphonic acid ≥98% (by TLC)

Supplier: ENZO LIFE SCIENCES

HNMPA is a membrane impermeable inhibitor of insulin receptor tyrosine kinase (IC50 = 100µM); in rat adipocytes (IC50 = 10µM). Inhibits serine and tyrosine autophosphorylation by the human insulin receptor.

Expand 2 Items

Bisindolylmaleimide IX methanesulphonate ≥98%

Supplier: ENZO LIFE SCIENCES

Cell-permeable PKC inhibitor. Selective for PKC (IC50=10nM) over CaM kinase II (IC50=17µM) and PKA (IC50=0.9µM). Induces apoptosis in various cell lines.

Expand 1 Items

Ilimaquinone ≥98% (by TLC)

Supplier: ENZO LIFE SCIENCES

ADP-ribosylation factor inhibitor

Expand 1 Items

L-744,832 ≥98% (by TLC)

Supplier: ENZO LIFE SCIENCES

Ras farnesyltransferase inhibitor. Induces tumor regression in transgenic mice with multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Induces p21 expression and arrests cells at G1. Causes enhanced mitotic sensitivity to taxol.

Expand 1 Items

Mevastatin sodium ≥98% (by HPLC)

Supplier: ENZO LIFE SCIENCES

This is the active carboxylate form of mevastatin. It is active in whole cells as well as in cell free assays.

Expand 1 Items

Farnesylthioacetic acid ≥98%

Supplier: ENZO LIFE SCIENCES

Methyltransferase inhibitor

Expand 2 Items

N-Arachidonoyl-L-phenylalanine ≥98% (by TLC)

Supplier: ENZO LIFE SCIENCES

Putative endogenous member of a growing family of lipo-amino acids (N-acyl amino acids).

Expand 1 Items

3-Methyl-1-phenyl-2-pyrazolin-5-one ≥98% (by HPLC)

Supplier: ENZO LIFE SCIENCES

A free radical scavenger and antioxidant. Displays beneficial effects in a rat model of ischemic brain damage.

Expand 2 Items

Virodhamine ≥98% (by TLC)

Supplier: ENZO LIFE SCIENCES

Cannabinoid receptor ligand.

Expand 1 Items

2,3-Diphenylquinoxaline-6-carboxylic acid ≥98% (by TLC)

Supplier: ENZO LIFE SCIENCES

Inhibits the translocation of Akt.

Expand 1 Items

3'-Carbamoyl-[1,1'-biphenyl]-3-ylcyclohexylcarbamate ≥98% (by TLC)

Supplier: ENZO LIFE SCIENCES

URB-597 is a potent and selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), which is involved in the hydrolysis of endogenous cannabinoids such as anandamide. Inhibition of FAAH may serve to enhance the analgesic effects of endogenous cannabinoids. URB-597 has been shown to inhibit FAAH in rat cortical neuron membranes and in intact neurons with IC50 values of 4.6nM and 0.5nM, respectively. The compound has also been shown to have anxiolytic effects in rats (ID50=0.15mg/kg). Because URB-597 acts on FAAH and does not interfere with the binding of anandamide to the CB1 and CB2 receptors, it is a novel tool for drug development.

Expand 1 Items

AG-1288 ≥98% (by TLC)

Supplier: ENZO LIFE SCIENCES

Tyrosine kinase inhibitor. It has been shown to block TNFα induced cytotoxicity and to block glucocorticoid-induced COX-2 activity in human amnion cells (IC50=21μM). It is also reported to inhibit guanylyl cyclase.

Expand 1 Items

Anandamide ≥98% (by TLC)

Supplier: ENZO LIFE SCIENCES

Endogenous [1] ligand for the CB1 receptor (CB1: Ki=52nm; CB2: Ki=1930nm [2]) and TRPV1 (Ki=5.78µM [3,4]). Inhibits NF-κB activation through direct binding to IKKβ [5] and induces apoptosis independently of cannabinoid or vanilloid receptors [6]. Activates the MAP kinase (MAPK/ERK) signalling pathway [7].

Expand 2 Items

BML-283 ≥98% (by TLC)

Supplier: ENZO LIFE SCIENCES

Pyruvate kinase M2 activator.

Expand 1 Items

Palmitoylethanolamide ≥98% (by TLC)

Supplier: ENZO LIFE SCIENCES

Endogenous cannabinoid. Weak ligand of CB1 (Ki=23.8µM) and CB2 (Ki=13.9µM) receptor. Inhibits fatty acid amide hydrolase (FAAH) (IC50=5.1µM). Immunosuppressant, anti-inflammatory, anti-nociceptive and anti-convulsant in vivo. The exact mode of action has not yet been revealed. It has been suggested that PEA: i) binds to a yet to be discovered cannabinoid receptor similar to CB2; ii) administered in vivo elicits the synthesis of endogenous agonists of CB2; iii) acts as an "entourage" compound by enhancing the activity and/or by influencing the turnover of endogenous agonists of CB2, possibly but not uniquely, by inhibiting their degradation.